<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0101-5907</journal-id>
<journal-title><![CDATA[Revista Paraense de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Para. Med.]]></abbrev-journal-title>
<issn>0101-5907</issn>
<publisher>
<publisher-name><![CDATA[Fundação Santa Casa de Misericórdia do Pará]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0101-59072006000400008</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Lesão da substância branca e doenças neurodegenerativas]]></article-title>
<article-title xml:lang="en"><![CDATA[White matter injury and neurodegenerative diseases]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[Rafael Rodrigues]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Ana Maria Rabelo]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[Renata Duarte de]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Claudia Dourado dos]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Joanilson Guimarães]]></given-names>
</name>
<xref ref-type="aff" rid="A05"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[Walace Gomes]]></given-names>
</name>
<xref ref-type="aff" rid="A06"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Doutorando em Neurociências e Biologia Celular (UFPA) Cirurgião-Dentista, Mestre em Neurociências e Biologia Celular, Discente do Programa de Pós-Graduação em Odontologia (UFPA) ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Mestre em Neurociências e Biologia Celular (UFPA) Farmacêutica-Bioquímica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Mestre em Neurociências e Biologia Celular (UFPA) Fisioterapeuta e Cirurgiã-Dentista ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A04">
<institution><![CDATA[,Mestre em Odontologia (UFPA) Cirurgiã-Dentista ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A05">
<institution><![CDATA[,Mestrando em Neurociências e Biologia Celular (UFPA) Biomédico ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A06">
<institution><![CDATA[,Professor Adjunto e Chefe do Laboratório de Neuroproteção e Neuroregeneração Experimental do Departamento de Morfologia, CCB-UFPA Doutor em Neurociências (Neuropatologia Experimental) Biomédico]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2006</year>
</pub-date>
<volume>20</volume>
<numero>4</numero>
<fpage>41</fpage>
<lpage>45</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S0101-59072006000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S0101-59072006000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S0101-59072006000400008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivo: revisar a literatura científica sobre degeneração da substância branca, incluindo lesão do cilindro axonal, da bainha de mielina e oligodendrócitos, enfatizando o papel deste evento patológico na perda tecidual e deficiências funcionais subjacentes às doenças neurodegenerativas agudas e crônicas. Método: revisão de literatura através de pesquisa bibliográfica na base de dados PUBMED/MEDLINE. Considerações Finais: o comprometimento patológico da substância branca é um mecanismo importante da fisiopatologia de doenças neurodegenerativas agudas e crônicas. Pesquisas translacionais nesta área devem ser realizadas para o desenvolvimento de novas abordagens terapêuticas para essas desordens neurais. Um objetivo importante destes estudos deve ser a proteção dos tratos de substância branca do sistema nervoso central humano, os quais podem degenerar durante doenças, incluindo trauma cerebral e medular, acidente vascular encefálico e esclerose múltipla.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objective: review the literature on the white matter pathology, including axonal damage, myelin impairment and oligodendrocyte degeneration, emphasizing the importance of this pathological event on the underlying functional deficits following neurodegenerative diseases. Method: bibliography search using PUBME/MEDLINE databases. Final considerations: the pathological impairment of white matter is an important mechanism underlying the pathophysiology of both acute and chronic neurodegenerative disorders. Translational researches should be accomplished for the development of new therapeutic approaches for human brain disorders. An important aim of these investigations must be the protection of the human white matter tracts, which are damaged following neural disorders, including brain and spinal cord trauma, stroke and multiple sclerosis.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[substância branca]]></kwd>
<kwd lng="pt"><![CDATA[lesão axonal]]></kwd>
<kwd lng="pt"><![CDATA[degeneração de oligodendrócitos]]></kwd>
<kwd lng="pt"><![CDATA[desmielinização]]></kwd>
<kwd lng="en"><![CDATA[white matter]]></kwd>
<kwd lng="en"><![CDATA[axonal damage]]></kwd>
<kwd lng="en"><![CDATA[oligodendrocyte degeneration]]></kwd>
<kwd lng="en"><![CDATA[demyelination]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b><a name="topo"></a>ATUALIZA&Ccedil;&Atilde;O/REVIS&Atilde;O</b></font></p>     <p>&nbsp;</p>     <p><font size="4" face="Verdana"><b>Les&atilde;o da subst&acirc;ncia branca e    doen&ccedil;as neurodegenerativas<sup><a href="#nota"><font size="3">1</font></a></sup></b></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>White matter injury and neurodegenerative    diseases</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Rafael Rodrigues Lima<sup>I</sup>; Ana Maria    Rabelo Costa<sup>II</sup>; Renata Duarte de Souza<sup>III</sup>; Claudia Dourado    dos Santos<sup>IV</sup>; Joanilson Guimarães-Silva<sup>V</sup>; Walace Gomes    Leal<sup>VI</sup></b></font></p>     <p><font size="2" face="Verdana"><sup>I</sup>Cirurgi&atilde;o-Dentista,    Mestre em Neuroci&ecirc;ncias e Biologia Celular, Discente do Programa de P&oacute;s-Gradua&ccedil;&atilde;o    em Odontologia (UFPA) e Doutorando em Neuroci&ecirc;ncias e Biologia Celular    (UFPA)    <br>   </font><font size="2" face="Verdana"><sup>II</sup>Farmac&ecirc;utica-Bioqu&iacute;mica,    Mestre em Neuroci&ecirc;ncias e Biologia Celular (UFPA)    ]]></body>
<body><![CDATA[<br>   </font><font size="2" face="Verdana"><sup>III</sup>Fisioterapeuta e Cirurgi&atilde;-Dentista.    Mestre em Neuroci&ecirc;ncias e Biologia Celular (UFPA)    <br>   </font><font size="2" face="Verdana"><sup>IV</sup>Cirurgi&atilde;-Dentista, Mestre    em Odontologia (UFPA)    <br>   </font><font size="2" face="Verdana"><sup>V</sup>Biom&eacute;dico. Mestrando    em Neuroci&ecirc;ncias e Biologia Celular (UFPA)    <br>   </font><font size="2" face="Verdana"><sup>VI</sup> Biom&eacute;dico. Doutor em    Neuroci&ecirc;ncias (Neuropatologia Experimental), Professor Adjunto e Chefe    do Laborat&oacute;rio de Neuroprote&ccedil;&atilde;o e Neuroregenera&ccedil;&atilde;o    Experimental do Departamento de Morfologia, CCB-UFPA.</font></p>     <p><font size="2" face="Verdana"><a href="#endereco">Endere&ccedil;o para correspond&ecirc;ncia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>RESUMO</b></font></p>     <p><font size="2" face="Verdana"><b><i>OBJETIVO:</i></b><i> revisar a literatura    cient&iacute;fica sobre degenera&ccedil;&atilde;o da subst&acirc;ncia branca,    incluindo les&atilde;o do cilindro axonal, da bainha de mielina e oligodendr&oacute;citos,    enfatizando o papel deste evento patol&oacute;gico na perda tecidual e defici&ecirc;ncias    funcionais subjacentes &agrave;s doen&ccedil;as neurodegenerativas agudas e    cr&ocirc;nicas.    <br>   <b>M&Eacute;TODO:</b> revis&atilde;o de literatura atrav&eacute;s de pesquisa    bibliogr&aacute;fica na base de dados PUBMED/MEDLINE.    ]]></body>
<body><![CDATA[<br>   <b> CONSIDERA&Ccedil;&Otilde;ES FINAIS:</b> o comprometimento patol&oacute;gico    da subst&acirc;ncia branca &eacute; um mecanismo importante da fisiopatologia    de doen&ccedil;as neurodegenerativas agudas e cr&ocirc;nicas. Pesquisas translacionais    nesta &aacute;rea devem ser realizadas para o desenvolvimento de novas abordagens    terap&ecirc;uticas para essas desordens neurais. Um objetivo importante destes    estudos deve ser a prote&ccedil;&atilde;o dos tratos de subst&acirc;ncia branca    do sistema nervoso central humano, os quais podem degenerar durante doen&ccedil;as,    incluindo trauma cerebral e medular, acidente vascular encef&aacute;lico e esclerose    m&uacute;ltipla.</i></font></p>     <p><font size="2" face="Verdana"><b>Descritores:</b> subst&acirc;ncia branca;    les&atilde;o axonal; degenera&ccedil;&atilde;o de oligodendr&oacute;citos; desmieliniza&ccedil;&atilde;o.</font></p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>SUMMARY</b></font></p>     <p><font size="2" face="Verdana"><b>OBJECTIVE:</b> review the literature on the    white matter pathology, including axonal damage, myelin impairment and oligodendrocyte    degeneration, emphasizing the importance of this pathological event on the underlying    functional deficits following neurodegenerative diseases.    <br>   <b> METHOD:</b> bibliography search using PUBME/MEDLINE databases.    <br>   <b> FINAL CONSIDERATIONS:</b> the pathological impairment of white matter is    an important mechanism underlying the pathophysiology of both acute and chronic    neurodegenerative disorders. Translational researches should be accomplished    for the development of new therapeutic approaches for human brain disorders.    An important aim of these investigations must be the protection of the human    white matter tracts, which are damaged following neural disorders, including    brain and spinal cord trauma, stroke and multiple sclerosis. </font></p>     <p><font size="2" face="Verdana"><b>Key Words</b>: white matter; axonal damage;    oligodendrocyte degeneration; demyelination</font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>INTRODU&Ccedil;&Atilde;O</b></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">O sistema nervoso central (SNC) &eacute; composto    pelas subst&acirc;ncias branca e cinzenta. Microscopicamente, a subst&acirc;ncia    cinzenta corresponde &agrave; regi&atilde;o de maior densidade de corpos neuronais,    enquanto que a subst&acirc;ncia branca possui alguns tipos neuronais, como as    c&eacute;lulas diaforase positivas e uma grande quantidade de ax&ocirc;nios    mielinizados, estrutura condicionante do aspecto esbranqui&ccedil;ado. Ambas    as regi&otilde;es, al&eacute;m dos neur&ocirc;nios, possuem grande quantidade    de c&eacute;lulas gliais, tanto da macr&oacute;glia (astr&oacute;citos e oligodendr&oacute;citos),    como da micr&oacute;glia (macr&oacute;fagos residentes). Os oligodendr&oacute;citos    s&atilde;o mais freq&uuml;entes na subst&acirc;ncia branca, onde formam a bainha    de mielina (o que fazem as c&eacute;lulas de Schwann no sistema nervoso perif&eacute;rico).    Os estudos neuropatol&oacute;gicos cl&aacute;ssicos foram mais centrados nas    altera&ccedil;&otilde;es patol&oacute;gicas que acometem a subst&acirc;ncia    cinzenta e negligenciado os eventos patol&oacute;gicos da subst&acirc;ncia branca<sup>1</sup>.    Esse cen&aacute;rio est&aacute; mudando, pois considera-se atualmente que a    les&atilde;o da subst&acirc;ncia branca possui um papel fundamental na g&ecirc;nese    dos d&eacute;ficits funcionais durante desordens neurais agudas e cr&ocirc;nicas<sup>2</sup>.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>OBJETIVO</b></font></p>     <p><font size="2" face="Verdana">Revisar a literatura cient&iacute;fica sobre    degenera&ccedil;&atilde;o da subst&acirc;ncia branca, incluindo les&atilde;o    do cilindro axonal, mielina e oligodendr&oacute;citos, enfatizando o papel deste    evento patol&oacute;gico na perda tecidual e nos d&eacute;ficits funcionais    subjacentes &agrave;s doen&ccedil;as neurodegenerativas agudas e cr&ocirc;nicas.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>M&Eacute;TODO</b></font></p>     <p><font size="2" face="Verdana">Pesquisa bibliogr&aacute;fica na base de dados    PUBMED (US National Library of Medicine e Institute of Health)/ MEDLINE.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>REVIS&Atilde;O DA LITERAURA</b></font></p>     <p><font size="2" face="Verdana">Os tratos de subst&acirc;ncia branca do SNC possuem    a importante fun&ccedil;&atilde;o de transportar sinais neurais de regi&otilde;es    subcorticais para o c&oacute;rtex e do c&oacute;rtex para as regi&otilde;es    subcorticais. No SNC, les&otilde;es isqu&ecirc;mica e traum&aacute;tica, freq&uuml;entemente,    resultam em d&eacute;ficit funcional significativo, maior parte do qual pode    ser atribu&iacute;do &agrave; disfun&ccedil;&atilde;o da subst&acirc;ncia branca    ao inv&eacute;s de disfun&ccedil;&atilde;o da subst&acirc;ncia cinzenta<sup>1-4</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Sabe-se que os efeitos lesivos de uma altera&ccedil;&atilde;o    patol&oacute;gica prim&aacute;ria no SNC, por exemplo, isquemia ou trauma, s&atilde;o    exacerbados durante o chamado processo de degenera&ccedil;&atilde;o secund&aacute;ria,    ou seja, o aumento progressivo da &aacute;rea de les&atilde;o prim&aacute;ria    para regi&otilde;es circunjacentes ou mesmo distantes do s&iacute;tio inicial    da les&atilde;o<sup>3,5</sup>. Os principais mecanismos envolvidos nesse evento, incluem    altera&ccedil;&otilde;es i&ocirc;nicas, excitotoxicidade, estresse oxidativo,    apoptose e resposta inflamat&oacute;ria<sup>3, 5-8</sup>.</font></p>     <p><font size="2" face="Verdana">Os mecanismos de morte celular em condi&ccedil;&otilde;es    neuropatol&oacute;gicas agudas e cr&ocirc;nicas envolvem, pelo menos parcialmente,    a ativa&ccedil;&atilde;o de receptores glutamat&eacute;rgicos do tipo AMPA/Kainato    e NMDA<sup>8</sup>. Durantes esses dist&uacute;rbios patol&oacute;gicos, acredita-se que    o ac&uacute;mulo excessivo de glutamato no meio extracelular, devido &agrave;s    altera&ccedil;&otilde;es metab&oacute;licas, induz ativa&ccedil;&atilde;o de    receptores glutamat&eacute;rgicos nas membranas celulares de neur&ocirc;nios    e c&eacute;lulas gliais, com subseq&uuml;ente influxo de cloreto (Cl<sup>-</sup>), &iacute;ons    s&oacute;dio (Na<sup>+</sup>) e c&aacute;lcio (Ca<sup>2+</sup>) para o meio intracelular<sup>8-9</sup>.</font></p>     <p><font size="2" face="Verdana">O influxo excessivo de Na<sup>+</sup> induz tumefa&ccedil;&atilde;o    intracelular e altera&ccedil;&atilde;o do equil&iacute;brio osm&oacute;tico<sup>8-9</sup>.    A entrada excessiva de Ca<sup>2+</sup> na c&eacute;lula ativa diversas proteases (por exemplo,    calpa&iacute;nas, fosfolipases e endonucleases) as quais podem degradar a maior    parte dos componentes estruturais dos neur&ocirc;nios<sup>8-9</sup>. A ativa&ccedil;&atilde;o    de certos tipos de fosfolipases durante excitoxicidade pode degradar lip&iacute;dios    da membrana celular, enquanto que endonucleases podem degradar o genoma da c&eacute;lula<sup>8-9</sup>.</font></p>     <p><font size="2" face="Verdana">Al&eacute;m de seus efeitos delet&eacute;rios    diretos, a ativa&ccedil;&atilde;o destas enzimas pode contribuir para a forma&ccedil;&atilde;o    de radicais livres, tais como o peroxinitrito e hidroxilas - que s&atilde;o    subst&acirc;ncias extremamente lesivas<sup>10</sup>. Por exemplo, fosfolipases ativadas    pelo Ca<sup>2+</sup> podem induzir libera&ccedil;&atilde;o de &aacute;cido araquid&ocirc;nico    da membrana plasm&aacute;tica com forma&ccedil;&atilde;o subsequente de radicais    livres<sup>8-10</sup>.</font></p>     <p><font size="2" face="Verdana">In&uacute;meros estudos experimentais confirmaram    - <i>in vitro</i> e <i>in vivo</i>- que concentra&ccedil;&otilde;es elevadas    de agonistas glutamat&eacute;rgicos, tais como o NMDA, induzem eventos lesivos    que incluem tumefa&ccedil;&atilde;o dendr&iacute;tica e de corpos celulares,    edema, degenera&ccedil;&atilde;o de organelas intracelulares, picnose, necrose,    al&eacute;m de resposta inflamat&oacute;ria<sup>8,9,11-12</sup>. Essas caracter&iacute;sticas    histopatol&oacute;gicas s&atilde;o encontradas em condi&ccedil;&otilde;es cl&iacute;nicas,    como trauma cerebral e da medula espinhal e acidente vascular encef&aacute;lico<sup>9</sup>.    Al&eacute;m disso, concentra&ccedil;&otilde;es elevadas de amino&aacute;cidos    excitat&oacute;rios s&atilde;o encontradas no l&iacute;quido c&eacute;falo-raquidiano    de pacientes que sofreram essas condi&ccedil;&otilde;es patol&oacute;gicas<sup>8,9</sup>.</font></p>     <p><font size="2" face="Verdana">Demonstrou-se experimentalmente que antagonistas    de receptores glutamat&eacute;rgicos, diminuem a &aacute;rea de les&atilde;o    excitot&oacute;xica ap&oacute;s trauma e isquemia induzida por oclus&atilde;o    da art&eacute;ria cerebral m&eacute;dia em ratos<sup>13</sup>. MK801, um antagonista de    receptores do tipo NMDA, foi utilizado com sucesso, demonstrando efeito neuroprotetor    em modelos experimentais<sup>13</sup>. No entanto, o uso terap&ecirc;utico de tal antagonista    n&atilde;o se mostrou muito promissor, principalmente, pelos efeitos colaterais    causados e pelo fato de que o MK801 parece proteger a subst&acirc;ncia cinzenta,    mas n&atilde;o a subst&acirc;ncia branca<sup>14-15</sup>.</font></p>     <p><font size="2" face="Verdana">Os eventos patol&oacute;gicos que acometem a    subst&acirc;ncia branca foram negligenciados no passado<sup>1-2</sup>, mas atualmente acredita-se    que os d&eacute;ficits funcionais gerados ap&oacute;s les&atilde;o traum&aacute;tica    do c&eacute;rebro e medula espinhal, acidentes vasculares e outras condi&ccedil;&otilde;es    patol&oacute;gicas agudas e cr&ocirc;nicas podem ser originados ap&oacute;s    les&atilde;o axonal<sup>1,2,14-23</sup>. O conhecimento dos mecanismos envolvidos nesse    processo &eacute; de fundamental import&acirc;ncia para o desenvolvimento de    futuras abordagens terap&ecirc;uticas para doen&ccedil;as neurol&oacute;gicas    humanas <sup>1,2, 4,14-28</sup>.</font></p>     <p><font size="2" face="Verdana">Ap&oacute;s les&atilde;o excitot&oacute;xica    experimental da medula espinhal de roedores demonstrou-se que uma les&atilde;o    prim&aacute;ria no corno ventral pode induzir eventos patol&oacute;gicos secund&aacute;rios    nos tratos de subst&acirc;ncia branca, incluindo les&atilde;o axonal e altera&ccedil;&otilde;es    na bainha de mielina da subst&acirc;ncia branca dorsal distante do s&iacute;tio    de les&atilde;o prim&aacute;ria<sup>12</sup>. Neste estudo, sugeriu-se uma correlac&atilde;o    entre resposta inflamat&oacute;ria e les&atilde;o axonal. Ap&oacute;s les&atilde;o    excitot&oacute;xica estriatal, demonstrou-se, experimentalmente, que a les&atilde;o    axonal &eacute; um fen&ocirc;meno tardio, que pode ocorrer 7 dias ap&oacute;s    a injec&atilde;o de NMDA no caudado-put&acirc;men<sup>25</sup>.</font></p>     <p><font size="2" face="Verdana">Les&atilde;o axonal e altera&ccedil;&otilde;es    da bainha de mielina s&atilde;o fen&ocirc;menos patol&oacute;gicos importantes    ap&oacute;s isquemia experimental em roedores<sup>23-24</sup>. Tanto no c&oacute;rtex motor    <sup>24</sup>, como no estriado<sup>23</sup>, altera&ccedil;&otilde;es progressivas na subst&acirc;ncia    branca s&atilde;o encontradas ap&oacute;s indu&ccedil;&atilde;o de isquemia    focal. Eventos patol&oacute;gicos similares foram descritos em seres humanos<sup>14-15,20</sup>.</font></p>     <p><font size="2" face="Verdana">Os mecanismos respons&aacute;veis pela les&atilde;o    da subst&acirc;ncia branca durante doen&ccedil;as neurodegenerativas come&ccedil;aram    a ser revelados<sup>4</sup>. Os mesmos foram mais investigados no nervo &oacute;ptico    e na medula espinhal, onde os efeitos lesivos na subst&acirc;ncia branca podem    ser melhor interpretados<sup>4,16-21</sup>. No nervo &oacute;ptico, 60 minutos    de an&oacute;xia s&atilde;o suficientes para induzir perda de microt&uacute;bulos    e neurofilamentos, componentes importantes do citoesqueleto axonal<sup>4</sup>.    Resultados similares foram obtidos ap&oacute;s 2-4h de isquemia cerebral focal<sup>4</sup>.    Na medula espinhal, altera&ccedil;&otilde;es do citoesqueleto e les&atilde;o    de oligodendr&oacute;citos foram descritas em modelos experimentais <i>in vivo</i>    e <i>in vitro</i><sup>26-28</sup>. Nessas condi&ccedil;&otilde;es experimentais, existem    fortes evid&ecirc;ncias que altera&ccedil;&otilde;es metab&oacute;licas com    subsequentes eventos excitot&oacute;xicos e/ou inflamat&oacute;rios s&atilde;o    respons&aacute;veis pela les&atilde;o da subst&acirc;ncia branca<sup>4, 26-28</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Uma conseq&uuml;&ecirc;ncia importante dos mecanismos    descritos acima &eacute; que ax&ocirc;nios da subst&acirc;ncia branca, incluindo    as fibras de passagem, podem ser lesados, gerando d&eacute;ficits funcionais    significativos<sup>1,2,4,14-22</sup>. Les&atilde;o de ax&ocirc;nios, mielina    e oligodendr&oacute;citos s&atilde;o comuns em certas condi&ccedil;&otilde;es    neurodegenerativas agudas e cr&ocirc;nicas em seres humanos<sup>2</sup>, particularmente    trauma, acidente vascular encef&aacute;lico, esclerose m&uacute;ltipla e na    esclerose lateral amiotr&oacute;fica<sup>19, 29-33</sup>.</font></p>     <p><font size="2" face="Verdana">No caso da esclerose m&uacute;ltipla, acredita-se    haver participa&ccedil;&atilde;o de componentes da resposta inflamat&oacute;ria    nos mecanismos subjacentes ao processo de desmieliniza&ccedil;&atilde;o caracter&iacute;stico    desta doen&ccedil;a<sup>19, 29-33</sup>. Subst&acirc;ncias sintetizadas e liberadas    por macr&oacute;fagos, linf&oacute;citos ou outro componente da resposta inflamat&oacute;ria,    tais como o fator de necrose tumoral (TNF-&#945;, do ingl&ecirc;s <i>tumor necrosis    factor &#945;</i>), podem lesar diretamente a mielina e mesmo o cilindro axonal<sup>19,29-33</sup>.</font></p>     <p><font size="2" face="Verdana">Um mecanismo envolvendo excitotoxidade mediada    por ativa&ccedil;&atilde;o excessiva de receptores AMPA/ Kainato, ap&oacute;s    revers&atilde;o de bombas metab&oacute;licas foi proposto para explicar a les&atilde;o    da subst&acirc;ncia branca ap&oacute;s les&atilde;o da medula espinhal<sup>26</sup></sup>, mas    este mesmo mecanismo pode estar envolvido em algumas doen&ccedil;as desmielinizantes    como a esclerose m&uacute;ltipla<sup>4,19</sup>.</font></p>     <p><font size="2" face="Verdana">Classicamente, a desmieliniza&ccedil;&atilde;o    foi considerada o principal evento histopatol&oacute;gico da esclerose m&uacute;ltipla,    mas demonstrou-se que les&atilde;o do cilindro axonal &eacute; um evento importante    nesta doen&ccedil;a neurodegenerativa<sup>29</sup>. O n&uacute;mero de ax&ocirc;nios lesados,    como demonstrado pela histoqu&iacute;mica para o precursor &#946; amil&oacute;ide    &#8211; um marcador sens&iacute;vel de les&atilde;o axonal<sup>34</sup> - p&ocirc;de ser    correlacionado com o n&uacute;mero de macr&oacute;fagos na &aacute;rea de placas    ativas em pacientes com esclerose m&uacute;ltipla<sup>29-30</sup>.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>CONSIDERA&Ccedil;&Otilde;ES FINAIS</b></font></p>     <p><font size="2" face="Verdana">Como aqui enfatizado, o comprometimento patol&oacute;gico    da susbst&acirc;ncia branca &eacute; um mecanismo importante da fisiopatologia    de doen&ccedil;as neurodegenerativas agudas e cr&ocirc;nicas. Pesquisas translacionais    nessa &aacute;rea devem ser realizadas para o desenvolvimento de novas abordagens    terap&ecirc;uticas. Um importante objetivo destes estudos deve ser a prote&ccedil;&atilde;o    dos tratos de subst&acirc;ncia branca do SNC humano que podem degenerar durante    doen&ccedil;as, incluindo trauma cerebral e medular e acidente vascular encef&aacute;lico.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>REFER&Ecirc;NCIAS</b></font></p>     <!-- ref --><p><font size="2" face="Verdana">1. COLEMAN, M. and PERRY, V. Axon Pathology in    Neurological Disease: A Neglected Therapeutic Target. <i>Trends in Neurosciences</i>    2002; 25:532.</font><!-- ref --><p><font size="2" face="Verdana">2. MEDANA, I.M and ESIRI, M.M. Axonal damage:    a key predictor of outcome in human CNS diseases. <i>Brain</i> 2003;126:515-530.</font><!-- ref --><p><font size="2" face="Verdana">3. BLIGHT, A.R. and DECRESCITO, V. Morphometric    Analysis of Experimental Spinal Cord Injury in the Cat: The Relation of Injury    Intensity to Survival of Myelinated Axons. <i>Neuroscience</i> 1986; 19:321-341.</font><!-- ref --><p><font size="2" face="Verdana">4. STYS, P.K. White matter injury mechanisms.    <i>Current Molecular Medicine</i> 2004; 4:113-130.</font><!-- ref --><p><font size="2" face="Verdana">5. FADEN, A.I. and SIMON, R.P. A Potential Role    for Excitotoxins in the Pathophysiology of Spinal Cord Injury. <i>Annals of    Neurology</i> 1988; 23:623-626.</font><!-- ref --><p><font size="2" face="Verdana">6. BRACKEN, M.B and HOLFORD, T.R. Neurological    and functional status 1 year after acute spinal cord injury: estimates of functional    recovery in National Acute Spinal Cord Injury Study II from results modeled    in National Acute Spinal Cord Injury Study III. <i>Journal of Neurosurgery</i>    2002; 96:259-266.</font><!-- ref --><p><font size="2" face="Verdana">7. YOLES, E.;MULLER, S. and SCHWARTZ, M. Nmda-Receptor    Antagonist Protects Neurons from Secondary Degeneration after Partial Optic    Nerve Crush. <i>Journal of Neurotrauma</i> 1997; 14:665-675.</font><!-- ref --><p><font size="2" face="Verdana">8. MELDRUM, B.S. Glutamate as a Neurotransmitter    in the Brain: Review of Physiology and Pathology.<i>Journal of Nutrition</i>    2000; 130:1007S-1015S.</font><!-- ref --><p><font size="2" face="Verdana">9. CHOI, D.W. Glutamate Neurotoxicity and Diseases    of the Nervous System. <i>Neuron</i> 1988; 1:623-634.</font><!-- ref --><p><font size="2" face="Verdana">10. LEWEN, A.; MATZ, P.; CHAN, P.H. Free radical    pathways in CNS injury. <i>Journal of Neurotrauma</i> 2000; 17:871-890.</font><!-- ref --><p><font size="2" face="Verdana">11. GOMES-LEAL W., CORKILL, D.J., FREIRE, M.A.M,    PICANCO-DINIZ, C.W.P., PERRY, V.H. Astrocytosis, microglia activation, oligodendrocyte    degeneration and pyknosis following acute spinal cord injury. <i>Experimental    Neurology</i> 2004; 190: 456-467.</font><!-- ref --><p><font size="2" face="Verdana">12. GOMES-LEAL W., CORKILL, D.J., PICANCO-DINIZ,    C.W.P. Systematic analysis of axonal damage and its possible correlation with    inflammatory response in different white matter tracts of acutely injured rat    spinal cord. <i>Brain Research</i> 2005; 1066: 57-70.</font><!-- ref --><p><font size="2" face="Verdana">13. MELDRUM, B.S. The Glutamate Synapse as a    Therapeutical Target: Perspectives for the Future. <i>Progress in Brain Research</i>    1998; 116:441-458.</font><!-- ref --><p><font size="2" face="Verdana">14. DEWAR, D.;YAM, P. and MCCULLOCH, J. Drug    Development for Stroke: Importance of Protecting Cerebral White Matter. <i>European    Journal of Pharmacology</i> 1999; 375:41-50.</font><!-- ref --><p><font size="2" face="Verdana">15. DE KEYSER, J.;SULTER, G. and LUITEN, P.G.    Clinical Trials with Neuroprotective Drugs in Acute Ischaemic Stroke: Are We    Doing the Right Thing? <i>Trends in Neurosciences</i> 1999; 22:535-540.</font><!-- ref --><p><font size="2" face="Verdana">16. AGRAWAL, S.K. and FEHLINGS, M.G. Mechanisms    of Secondary Injury to Spinal Cord Axons in Vitro: Role of Na+, Na(+)-K(+)-    Atpase, the Na(+)-H+ Exchanger, and the Na(+)-Ca2+ Exchanger. <i>Journal of    Neuroscience</i> 1996; 16:545-552.</font><!-- ref --><p><font size="2" face="Verdana">17. AGRAWAL, S.K. and FEHLINGS, M.G. Role of    Nmda and Non-Nmda Ionotropic Glutamate Receptors in Traumatic Spinal Cord Axonal    Injury. <i>Journal of Neuroscience</i> 1997; 17:1055-1063.</font><!-- ref --><p><font size="2" face="Verdana">18. MATUTE, C. Characteristics of Acute and Chronic    Kainate Excitotoxic Damage to the Optic Nerve. <i>Proceedings of the National    Academy of Sciences of the United States of America</i> 1998; 95:10229-10234.</font><!-- ref --><p><font size="2" face="Verdana">19. MATUTE, C.; ALBERDI, E.; DOMERCQ, M.; PEREZ    CERDA, F.; PEREZ SAMARTIN, A. and SANCHEZ GOMEZ, M.V. The Link between Excitotoxic    Oligodendroglial Death and Demyelinating Diseases. <i>Trends in Neurosciences</i>    2001; 24:224-230.</font><!-- ref --><p><font size="2" face="Verdana">20. PETTY, M.A. and WETTSTEIN, J.G. White Matter    Ischaemia. <i>Brain Research Reviews</i> 1999; 31:58-64.</font><!-- ref --><p><font size="2" face="Verdana">21. KANELLOPOULOS, G.K.;XU, X.M.;HSU, C.Y.;LU,    X.;SUNDT, T.M. and KOUCHOUKOS, N.T. White Matter Injury in Spinal Cord Ischemia:    Protection by Ampa/Kainate Glutamate Receptor Antagonism. <i>Stroke</i> 2000;    31:1945-1952.</font><!-- ref --><p><font size="2" face="Verdana">22. RAFF, M.C.;WHITMORE, A.V. and FINN, J.T.    Axonal Self-Destruction and Neurodegeneration. <i>Science</i> 2002; 296:868-871.</font><!-- ref --><p><font size="2" face="Verdana">23.DE SOUZA, R.D. Degenera&ccedil;&atilde;o da    subst&acirc;ncia branca ap&oacute;s isquemia focal no estriado de ratos adultos.    Disserta&ccedil;&atilde;o de Mestrado 2006. Universidade Federal do Par&aacute;,    Departamento de Morfologia.CCB.</font><!-- ref --><p><font size="2" face="Verdana">24. COSTA, A.M.R. Les&atilde;o axonal e Altera&ccedil;&otilde;es    Progressivas na Bainha de Mielina ap&oacute;s Les&atilde;o Isqu&ecirc;mica Focal    no C&oacute;rtex Motor de Ratos Adultos. Disserta&ccedil;&atilde;o de Mestrado    2006. Universidade Federal do Par&aacute;, Departamento de Morfologia, CCB.</font><!-- ref --><p><font size="2" face="Verdana">25.LIMA, R.R. les&atilde;o axonal e Resposta    Inflamat&oacute;ria Aguda ap&oacute;s Les&atilde;o excitot&oacute;xica do Estriado.    Disserta&ccedil;&atilde;o de Mestrado 2006. Universidade Federal do Par&aacute;.    Departamento de Morfologia, CCB.</font><!-- ref --><p><font size="2" face="Verdana">26. LI, S.;MEALING, G.A.;MORLEY, P. and STYS,    P.K. Novel Injury Mechanism in Anoxia and Trauma of Spinal Cord White Matter:    Glutamate Release Via Reverse Na+-Dependent Glutamate Transport. <i>Journal    of Neuroscience</i> 1999; 19:RC16.</font><!-- ref --><p><font size="2" face="Verdana">27. LI, S. and STYS, P.K. Mechanisms of Ionotropic    Glutamate Receptor-Mediated Excitotoxicity in Isolated Spinal Cord White Matter.    <i>Journal of Neuroscience</i> 2000; 20:1190-1198,.</font><!-- ref --><p><font size="2" face="Verdana">28. LI, S.;JIANG, Q. and STYS, P.K. Important    Role of Reverse Na(+)-Ca(2+) Exchange in Spinal Cord White Matter Injury at    Physiological Temperature. <i>Journal of Neurophysiology</i> 2000; 84:1116-1119,</font><!-- ref --><p><font size="2" face="Verdana">29. FERGUSON, B.;MATYSZAK, M.K.;ESIRI, M.M. and    PERRY, V.H. Axonal Damage in Acute Multiple Sclerosis Lesions. <i>Brain</i>    1997; 120:393-399.</font><!-- ref --><p><font size="2" face="Verdana">30. TRAPP, B.D.;PETERSON, J.;RANSOHOFF, R.M.;RUDICK,    R.;MORK, S. and BO, L. Axonal Transection in the Lesions of Multiple Sclerosis.    <i>New England Journal of Medicine</i> 1998; 338:278-285.</font><!-- ref --><p><font size="2" face="Verdana">31. TRAPP, B.D.;BO, L.;MORK, S. and CHANG, A.    Pathogenesis of Tissue Injury in Ms Lesions. <i>Journal of Neuroimmunology</i>    1999; 98:49-56.</font><!-- ref --><p><font size="2" face="Verdana">32. TRAPP, B.D.;RANSOHOFF, R. and RUDICK, R.    Axonal Pathology in Multiple Sclerosis: Relationship to Neurologic Disability.    <i>Current Opinion in Neurology</i> 1999; 12:295-302.</font><!-- ref --><p><font size="2" face="Verdana">33. BITSCH, A.;SCHUCHARDT, J.;BUNKOWSKI, S.;KUHLMANN,    T. and BRUCK, W. Acute Axonal Injury in Multiple Sclerosis. Correlation with    Demyelination and Inflammation. <i>Brain</i> 2000; 123:1174-1183.</font><!-- ref --><p><font size="2" face="Verdana">34. GENTLEMAN, S.M.;NASH, M.J.;SWEETING, C.J.;GRAHAM,    D.I. and ROBERTS, G.W. Beta-Amyloid Precursor Protein (Beta App) as a Marker    for Axonal Injury after Head Injury. <i>Neuroscience Letters</i> 1993; 160:139-144.</font><p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b><a name="endereco"></a><a href="#topo"><img src="/img/revistas/rpm/v20n4/seta.gif" border="0"></a>Endere&ccedil;o    para correspond&ecirc;ncia:</b>    <br>   Rafael Rodrigues Lima    <br>   Conjunto Panorama XXI Quadra 31 Casa 17    <br>   Nova Marambaia CEP66625-010 Bel&eacute;m &#8211; Par&aacute; &#8211; Brasil    <br>   Tel: (91) 8137-0833    ]]></body>
<body><![CDATA[<br>   E-mail: <a href="mailto:rafalima@ufpa.br">rafalima@ufpa.br</a></font></p>     <p><font size="2" face="Verdana">Recebido em 16.10.2006    <br>   Aprovado em 29.11.2006</font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><sup><a name="nota"></a><a href="#topo">1</a></sup>Trabalho    realizado no Laborat&oacute;rio de Neuroprote&ccedil;&atilde;o e Neuroregenera&ccedil;&atilde;o    Experimental do Centro de Ci&ecirc;ncias Biol&oacute;gicas da Universidade Federal    do Par&aacute; (CCB-UFPA)</font></p>     <p>&nbsp;</p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COLEMAN]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[PERRY]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Axon Pathology in Neurological Disease: A Neglected Therapeutic Target]]></article-title>
<source><![CDATA[Trends in Neurosciences]]></source>
<year>2002</year>
<volume>25</volume>
<page-range>532</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MEDANA]]></surname>
<given-names><![CDATA[I.M]]></given-names>
</name>
<name>
<surname><![CDATA[ESIRI]]></surname>
<given-names><![CDATA[M.M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Axonal damage: a key predictor of outcome in human CNS diseases]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2003</year>
<volume>126</volume>
<page-range>515-530</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BLIGHT]]></surname>
<given-names><![CDATA[A.R]]></given-names>
</name>
<name>
<surname><![CDATA[DECRESCITO]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Morphometric Analysis of Experimental Spinal Cord Injury in the Cat: The Relation of Injury Intensity to Survival of Myelinated Axons]]></article-title>
<source><![CDATA[Neuroscience]]></source>
<year>1986</year>
<volume>19</volume>
<page-range>321-341</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[STYS]]></surname>
<given-names><![CDATA[P.K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[White matter injury mechanisms]]></article-title>
<source><![CDATA[Current Molecular Medicine]]></source>
<year>2004</year>
<volume>4</volume>
<page-range>113-130</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FADEN]]></surname>
<given-names><![CDATA[A.I]]></given-names>
</name>
<name>
<surname><![CDATA[SIMON]]></surname>
<given-names><![CDATA[R.P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A Potential Role for Excitotoxins in the Pathophysiology of Spinal Cord Injury]]></article-title>
<source><![CDATA[Annals of Neurology]]></source>
<year>1988</year>
<volume>23</volume>
<page-range>623-626</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BRACKEN]]></surname>
<given-names><![CDATA[M.B]]></given-names>
</name>
<name>
<surname><![CDATA[HOLFORD]]></surname>
<given-names><![CDATA[T.R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III]]></article-title>
<source><![CDATA[Journal of Neurosurgery]]></source>
<year>2002</year>
<volume>96</volume>
<page-range>259-266</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[YOLES]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[MULLER]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[SCHWARTZ]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nmda-Receptor Antagonist Protects Neurons from Secondary Degeneration after Partial Optic Nerve Crush]]></article-title>
<source><![CDATA[Journal of Neurotrauma]]></source>
<year>1997</year>
<volume>14</volume>
<page-range>665-675</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MELDRUM]]></surname>
<given-names><![CDATA[B.S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology]]></article-title>
<source><![CDATA[Journal of Nutrition]]></source>
<year>2000</year>
<volume>130</volume>
<page-range>1007S-1015S</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHOI]]></surname>
<given-names><![CDATA[D.W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glutamate Neurotoxicity and Diseases of the Nervous System]]></article-title>
<source><![CDATA[Neuron]]></source>
<year>1988</year>
<volume>1</volume>
<page-range>623-634</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LEWEN]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MATZ]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[CHAN]]></surname>
<given-names><![CDATA[P.H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Free radical pathways in CNS injury]]></article-title>
<source><![CDATA[Journal of Neurotrauma]]></source>
<year>2000</year>
<volume>17</volume>
<page-range>871-890</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOMES-LEAL]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[CORKILL]]></surname>
<given-names><![CDATA[D.J]]></given-names>
</name>
<name>
<surname><![CDATA[FREIRE]]></surname>
<given-names><![CDATA[M.A.M]]></given-names>
</name>
<name>
<surname><![CDATA[PICANCO-DINIZ]]></surname>
<given-names><![CDATA[C.W.P]]></given-names>
</name>
<name>
<surname><![CDATA[PERRY]]></surname>
<given-names><![CDATA[V.H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Astrocytosis, microglia activation, oligodendrocyte degeneration and pyknosis following acute spinal cord injury]]></article-title>
<source><![CDATA[Experimental Neurology]]></source>
<year>2004</year>
<volume>190</volume>
<page-range>456-467</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOMES-LEAL]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[CORKILL]]></surname>
<given-names><![CDATA[D.J]]></given-names>
</name>
<name>
<surname><![CDATA[PICANCO-DINIZ]]></surname>
<given-names><![CDATA[C.W.P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systematic analysis of axonal damage and its possible correlation with inflammatory response in different white matter tracts of acutely injured rat spinal cord]]></article-title>
<source><![CDATA[Brain Research]]></source>
<year>2005</year>
<volume>1066</volume>
<page-range>57-70</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MELDRUM]]></surname>
<given-names><![CDATA[B.S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Glutamate Synapse as a Therapeutical Target: Perspectives for the Future]]></article-title>
<source><![CDATA[Progress in Brain Research]]></source>
<year>1998</year>
<volume>116</volume>
<page-range>441-458</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DEWAR]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[YAM]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[MCCULLOCH]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Drug Development for Stroke: Importance of Protecting Cerebral White Matter]]></article-title>
<source><![CDATA[European Journal of Pharmacology]]></source>
<year>1999</year>
<volume>375</volume>
<page-range>41-50</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DE KEYSER]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[SULTER]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[LUITEN]]></surname>
<given-names><![CDATA[P.G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical Trials with Neuroprotective Drugs in Acute Ischaemic Stroke: Are We Doing the Right Thing]]></article-title>
<source><![CDATA[Trends in Neurosciences]]></source>
<year>1999</year>
<volume>22</volume>
<page-range>535-540</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AGRAWAL]]></surname>
<given-names><![CDATA[S.K]]></given-names>
</name>
<name>
<surname><![CDATA[FEHLINGS]]></surname>
<given-names><![CDATA[M.G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mechanisms of Secondary Injury to Spinal Cord Axons in Vitro: Role of Na+, Na(+)-K(+)- Atpase, the Na(+)-H+ Exchanger, and the Na(+)-Ca2+ Exchanger]]></article-title>
<source><![CDATA[Journal of Neuroscience]]></source>
<year>1996</year>
<volume>16</volume>
<page-range>545-552</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AGRAWAL]]></surname>
<given-names><![CDATA[S.K]]></given-names>
</name>
<name>
<surname><![CDATA[FEHLINGS]]></surname>
<given-names><![CDATA[M.G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of Nmda and Non-Nmda Ionotropic Glutamate Receptors in Traumatic Spinal Cord Axonal Injury]]></article-title>
<source><![CDATA[Journal of Neuroscience]]></source>
<year>1997</year>
<volume>17</volume>
<page-range>1055-1063</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MATUTE]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Characteristics of Acute and Chronic Kainate Excitotoxic Damage to the Optic Nerve]]></article-title>
<source><![CDATA[Proceedings of the National Academy of Sciences of the United States of America]]></source>
<year>1998</year>
<volume>95</volume>
<page-range>10229-10234</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MATUTE]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[ALBERDI]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[DOMERCQ]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[PEREZ CERDA]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[PEREZ SAMARTIN]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[SANCHEZ GOMEZ]]></surname>
<given-names><![CDATA[M.V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Link between Excitotoxic Oligodendroglial Death and Demyelinating Diseases]]></article-title>
<source><![CDATA[Trends in Neurosciences]]></source>
<year>2001</year>
<volume>24</volume>
<page-range>224-230</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PETTY]]></surname>
<given-names><![CDATA[M.A]]></given-names>
</name>
<name>
<surname><![CDATA[WETTSTEIN]]></surname>
<given-names><![CDATA[J.G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[White Matter Ischaemia]]></article-title>
<source><![CDATA[Brain Research Reviews]]></source>
<year>1999</year>
<volume>31</volume>
<page-range>58-64</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KANELLOPOULOS]]></surname>
<given-names><![CDATA[G.K]]></given-names>
</name>
<name>
<surname><![CDATA[XU]]></surname>
<given-names><![CDATA[X.M]]></given-names>
</name>
<name>
<surname><![CDATA[HSU]]></surname>
<given-names><![CDATA[C.Y]]></given-names>
</name>
<name>
<surname><![CDATA[LU]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[SUNDT]]></surname>
<given-names><![CDATA[T.M]]></given-names>
</name>
<name>
<surname><![CDATA[KOUCHOUKOS]]></surname>
<given-names><![CDATA[N.T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[White Matter Injury in Spinal Cord Ischemia: Protection by Ampa/Kainate Glutamate Receptor Antagonism]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2000</year>
<volume>31</volume>
<page-range>1945-1952</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAFF]]></surname>
<given-names><![CDATA[M.C]]></given-names>
</name>
<name>
<surname><![CDATA[WHITMORE]]></surname>
<given-names><![CDATA[A.V]]></given-names>
</name>
<name>
<surname><![CDATA[FINN]]></surname>
<given-names><![CDATA[J.T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Axonal Self-Destruction and Neurodegeneration]]></article-title>
<source><![CDATA[Science]]></source>
<year>2002</year>
<volume>296</volume>
<page-range>868-871</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DE SOUZA]]></surname>
<given-names><![CDATA[R.D]]></given-names>
</name>
</person-group>
<source><![CDATA[Degeneração da substância branca após isquemia focal no estriado de ratos adultos]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COSTA]]></surname>
<given-names><![CDATA[A.M.R]]></given-names>
</name>
</person-group>
<source><![CDATA[Lesão axonal e Alterações Progressivas na Bainha de Mielina após Lesão Isquêmica Focal no Córtex Motor de Ratos Adultos]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LIMA]]></surname>
<given-names><![CDATA[R.R]]></given-names>
</name>
</person-group>
<source><![CDATA[lesão axonal e Resposta Inflamatória Aguda após Lesão excitotóxica do Estriado]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[MEALING]]></surname>
<given-names><![CDATA[G.A]]></given-names>
</name>
<name>
<surname><![CDATA[MORLEY]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[STYS]]></surname>
<given-names><![CDATA[P.K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Novel Injury Mechanism in Anoxia and Trauma of Spinal Cord White Matter: Glutamate Release Via Reverse Na+-Dependent Glutamate Transport]]></article-title>
<source><![CDATA[Journal of Neuroscience]]></source>
<year>1999</year>
<volume>19</volume>
<page-range>16</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[STYS]]></surname>
<given-names><![CDATA[P.K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mechanisms of Ionotropic Glutamate Receptor-Mediated Excitotoxicity in Isolated Spinal Cord White Matter]]></article-title>
<source><![CDATA[Journal of Neuroscience]]></source>
<year>2000</year>
<volume>20</volume>
<page-range>1190-1198</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[JIANG]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[STYS]]></surname>
<given-names><![CDATA[P.K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Important Role of Reverse Na(+)-Ca(2+) Exchange in Spinal Cord White Matter Injury at Physiological Temperature]]></article-title>
<source><![CDATA[Journal of Neurophysiology]]></source>
<year>2000</year>
<volume>84</volume>
<page-range>1116-1119</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FERGUSON]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[MATYSZAK]]></surname>
<given-names><![CDATA[M.K]]></given-names>
</name>
<name>
<surname><![CDATA[ESIRI]]></surname>
<given-names><![CDATA[M.M]]></given-names>
</name>
<name>
<surname><![CDATA[PERRY]]></surname>
<given-names><![CDATA[V.H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Axonal Damage in Acute Multiple Sclerosis Lesions]]></article-title>
<source><![CDATA[Brain]]></source>
<year>1997</year>
<volume>120</volume>
<page-range>393-399</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TRAPP]]></surname>
<given-names><![CDATA[B.D]]></given-names>
</name>
<name>
<surname><![CDATA[PETERSON]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[RANSOHOFF]]></surname>
<given-names><![CDATA[R.M]]></given-names>
</name>
<name>
<surname><![CDATA[RUDICK]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[MORK]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[BO]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Axonal Transection in the Lesions of Multiple Sclerosis]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>1998</year>
<volume>338</volume>
<page-range>278-285</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TRAPP]]></surname>
<given-names><![CDATA[B.D]]></given-names>
</name>
<name>
<surname><![CDATA[BO]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[MORK]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[CHANG]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pathogenesis of Tissue Injury in Ms Lesions]]></article-title>
<source><![CDATA[Journal of Neuroimmunology]]></source>
<year>1999</year>
<volume>98</volume>
<page-range>49-56</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TRAPP]]></surname>
<given-names><![CDATA[B.D]]></given-names>
</name>
<name>
<surname><![CDATA[RANSOHOFF]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[RUDICK]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Axonal Pathology in Multiple Sclerosis: Relationship to Neurologic Disability]]></article-title>
<source><![CDATA[Current Opinion in Neurology]]></source>
<year>1999</year>
<volume>12</volume>
<page-range>295-302</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BITSCH]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[SCHUCHARDT]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[BUNKOWSKI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[KUHLMANN]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[BRUCK]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acute Axonal Injury in Multiple Sclerosis: Correlation with Demyelination and Inflammation]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2000</year>
<volume>123</volume>
<page-range>1174-1183</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GENTLEMAN]]></surname>
<given-names><![CDATA[S.M]]></given-names>
</name>
<name>
<surname><![CDATA[NASH]]></surname>
<given-names><![CDATA[M.J]]></given-names>
</name>
<name>
<surname><![CDATA[SWEETING]]></surname>
<given-names><![CDATA[C.J]]></given-names>
</name>
<name>
<surname><![CDATA[GRAHAM]]></surname>
<given-names><![CDATA[D.I]]></given-names>
</name>
<name>
<surname><![CDATA[ROBERTS]]></surname>
<given-names><![CDATA[G.W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beta-Amyloid Precursor Protein (Beta App) as a Marker for Axonal Injury after Head Injury]]></article-title>
<source><![CDATA[Neuroscience Letters]]></source>
<year>1993</year>
<volume>160</volume>
<page-range>139-144</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
